Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Oncothyreon Inc. (ONTY - Snapshot Report) and its partner, Merck KGaA recently presented disappointing data from a phase III trial on their oncology candidate, L-BLP25 (formerly referred to as Stimuvax). L-BLP25 is being developed for the treatment of unresectable stage III non-small cell lung cancer (NSCLC).

The multi-center, randomized, double-blind, placebo-controlled START trial enrolled more than 1,500 patients. The trial evaluated efficacy, safety and tolerability of L-BLP25 in patients with unresectable, stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemoradiotherapy. It was found that the use of L-BLP25 did not improve overall survival (OS) significantly and did not meet the primary end point.

However, in certain subgroups, treatment benefit was observed. The companies plan to analyze the data further. Detailed data from the START trial will be presented at upcoming scientific meetings.

Currently, a second phase III trial, INSPIRE, is ongoing. The trial is evaluating L-BLP25 in patients of Asian heritage suffering from unresectable, stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemoradiotherapy.

In 2007, Merck KGaA had gained development and commercialization rights to L-BLP25 from Oncothyreon. In Japan, Merck KGaA has a co-development and marketing agreement with a Japanese pharma company, Ono Pharmaceutical Co. Ltd.

We currently have a Neutral recommendation on Oncothyreon. The stock carries a Zacks #3 Rank (Hold) in the short run.

Pharma stocks that currently look more attractive include companies like Allergan (AGN - Analyst Report), AstraZeneca (AZN - Analyst Report) and Novo Nordisk (NVO - Analyst Report). All these companies carries a Zacks #2 Rank (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%